Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term…
Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimo
How this was made
The 30-second read
Why it matters
The successful formulation work is a technical milestone that could broaden the product's market size dramatically if systemic exposure is demonstrated and regulatory approval is obtained.
Market read
The announcement may lift VBIO's valuation as investors reassess the long‑term market potential for a needle‑free ARS treatment.
What to watch
Funding requirements for further trials and competition from other ARS countermeasures could temper expectations.
Background
Valion Bio (NASDAQ: VBIO) is developing Entolimod as a medical countermeasure for acute radiation syndrome. The company partnered with Shear Kershman Laboratories to create an oral gel formulation using the BioViscid™ platform.
Ticker impact
Valion Bio filed an 8‑K announcing successful formulation of an oral mucosal Entolimod delivery, a new development milestone for the company.
likely upward pressure as investors price in the expanded market opportunity and future regulatory milestones.
First disclosure of a technical breakthrough; no immediate revenue but significant long‑term upside potential.
Market effects
May boost the biotech/medical countermeasure sector as oral delivery platforms gain credibility.
Limited to U.S. and defense‑related procurement markets.
Potential interest from governments worldwide seeking radiological emergency countermeasures.
Counterpoint
The oral formulation may face regulatory hurdles and uncertain demand, limiting near‑term impact.
Key entities
- companyValion Bio, Inc.
Developer of Entolimod, a radiological emergency countermeasure.
- companyShear Kershman Laboratories
Partner providing the BioViscid™ drug‑delivery platform.
